| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -16,497,223 | -12,486,450 |
| Change in fair value of warrant liabilities | -44,504 | -72,320 |
| Stock-based compensation expense | 1,772,775 | 1,314,396 |
| Prepaid clinical trial costs (current and non-current) | -458,859 | -436,154 |
| Prepaid expenses and other current assets | -418,508 | -319,471 |
| Accounts payable | -1,210,527 | -1,535,859 |
| Accrued expenses and other current liabilities | -3,694,320 | -1,182,338 |
| Net cash used in operating activities | -18,796,432 | -13,206,946 |
| Proceeds from issuance of short-term debt | 0 | 0 |
| Repayment of short-term debt | 458,154 | 344,908 |
| Proceeds from issuance of common stock in atm offering, net of transaction costs-The Market Offering Agreement Atm Agreement | 1,300,686 | 988,112 |
| Proceeds from issuance of common stock, common stock warrants, prefunded warrants and from modification of existing warrants, in offerings, net of transaction costs | 17,419,703 | 9,210,000 |
| Proceeds from exercise of common stock warrants-Common Stock Warrants | 241,125 | 241,125 |
| Net cash provided by financing activities | 18,503,360 | 10,094,329 |
| Net decrease in cash and cash equivalents | -293,072 | -3,112,617 |
| Cash and cash equivalents at beginning of period | 13,476,331 | - |
| Cash and cash equivalents at end of period | 13,183,259 | - |
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW)
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPHW)